Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma

Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single‐agent Len may be effective as prolonged treatment regimen in RRMM once patients demonstrate an initial response to Len+Dex induction. Patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Lund, Johan, Gruber, Astrid, Lauri, Birgitta, Duru, Adil Doganay, Blimark, Cecilie, Swedin, Agneta, Hansson, Markus, Forsberg, Karin, Ahlberg, Lucia, Carlsson, Conny, Waage, Anders, Gimsing, Peter, Vangsted, Annette Juul, Frølund, Ulf, Holmberg, Erik, Gahrton, Gösta, Alici, Evren, Hardling, Mats, Mellqvist, Ulf‐Henrik, Nahi, Hareth
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6010717/
https://ncbi.nlm.nih.gov/pubmed/29673108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1422
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados